Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thought-Controlled Prosthetics Get US FDA 'Leapfrog' Treatment

Executive Summary

A new "leapfrog" draft guidance from the US agency addresses implanted brain-computer interface prosthetic devices, and, specifically, the information sponsors should be prepared to submit for pre-submissions meetings and investigational device exemptions.

You may also be interested in...



US FDA ‘Leapfrogs’ Guidance On Brain-Computer Interface Devices

The technology could allow people with paralysis to operate computer-controlled prosthetic limbs and other devices with their thoughts.

Global Medtech Guidance Tracker: February 2019

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-six new guidance documents have been posted on the tracker since its last update.

Brain-Computer Interface Device Makers Must Consider Accessibility And Deployability

Brain-computer interface device makers should consider customer accessibility and clinicians’ ability to deploy the BCI system to get to market, Medtronic technology director says at an FDA meeting. New brain-machine interface include products to help paraplegics walk and people with tremors to grasp tools used in daily life.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel